Scroll over the words in bold for brief definitions.

Diagnosing Cryopyrin-Associated Periodic Syndromes (CAPS)

CAPS—A Rare, Lifelong Disease1-3

CAPS is a group of rare, genetic diseases that include Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).1-3

Prevalence of CAPS is estimated at 1 in 1 million. Approximately 300 patients are estimated to suffer from CAPS in the United States.2

  • CAPS is caused by genetic mutations, often in the NLRP3 (or CIAS1) gene2,3
    • These mutations result in overproduction of the proinflammatory cytokine, interleukin-1 beta (IL-1β)1
  • Without treatment, debilitating and recurrent symptoms of CAPS can disable patients for hours or last for days4-6
  • CAPS can remain undiagnosed and untreated due to the rarity of the disease and the resemblance of symptoms to other conditions2,7

Diagnosing CAPS

CAPS is a challenging differential diagnosis. While symptoms may resemble other illnesses, CAPS symptoms are chronic in nature.8

If a patient reports any of the following symptoms of CAPS on a daily or ongoing basis, or in response to changes in temperature or the environment, a diagnosis of Familial Cold Autoinflammatory Syndrome ( FCAS) or Muckle-Wells Syndrome (MWS) may be considered:


CAPS—A Familial Disease

  • Genetic mutations in the NLRP3 (or CIAS1) gene are usually autosomal-dominant inherited mutations2,3
  • Knowledge of the family connections in CAPS can be valuable to the health of future generations:
    • A link to an ancestor with CAPS may be revealed
    • Another family member presently suffering from the disease may be diagnosed

Use the downloadable assessment below to help you when identifying and diagnosing CAPS patients in your practice.

ILARIS® Patient Support Program

The ILARIS® Patient Support Program provides patients with information and tools to assist in managing their treatment with ILARIS® and helps to identify resources that can assist with payment for their medication.
Learn More

Register for ILARIS Updates

Sign up here for ILARIS® Direct and stay current with news about ILARIS®.

CAPS Signs and Symptoms Assessment

A brief assessment that can be referenced in-office when seeing patients. If a patient experiences any of these signs or symptoms on an ongoing basis, a diagnosis of CAPS may be considered.

Download Now

How This Web Site Can Help

This helpful online resource for health care professionals will provide you with general information about CAPS, including diagnosing CAPS, and other resources for you and your patients. Click any of the following links to learn more about CAPS:


Once diagnosed, effective treatment can help to relieve the signs and symptoms of CAPS.

References:

  • 1. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319-325.
  • 2. Toker O, Hashkes PJ. Prevalence of Cryopyrin-Associated Periodic Syndrome (CAPS) Biologics. 2010;4:131-138.
  • 3. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301-305.
  • 4. Hawkins PN, Lachmann HJ, Aganna E, Dermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004;50:607-612.
  • 5. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol. 2001;108:615-620.
  • 6. Watts RA, Nicholls A, Scott DGI. Case report: the arthropathy of the Muckle-Wells syndrome. Br J Rheumatol. 1994;33:1184-1187.
  • 7. Gattorno M, Federici S, Pelagatti MA, et al. Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol. 2008;28 (suppl 1):S73-S83.
  • 8. Hoffman HM. Hereditary immunologic disorders caused by pyrin and cryopyrin. Curr Allergy Asthma Rep. 2007;7:323-330.




isi-Professional www.fda.gov/medwatch full prescribing information